AKEBIA THERAPEUTICS, INC. Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2026-08-05: Form 10-Q; Exhibit 10.3; Description Amendment # 2, effective as of April 28, 2026, to Supply Agreement, dated as of February 10, 2021, by and between Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited..
- 2026-08-05: Form 10-Q; Exhibit 10.2; Description Amendment # 4, effective as of April 28, 2026, to Supply Agreement, dated as of April 2, 2020, by and between Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited..
- 2026-08-05: Form 10-Q; Exhibit 10.1; Description Eight Amendment to Lease between CLPF-Cambridge Science Center, LLC and Akebia Therapeutics, Inc., dated April 7, 2026..
- 2026-02-26: Form 10-K; Exhibit 10.98; Description Amendment #1 to License Agreement by and between Cyclerion Therapeutics, Inc. and Akebia Therapeutics, Inc. dated December 13, 2024.
| Filed | Form | Exhibit | Description |
|---|
| 2026-08-05 | 10-Q | 10.3 | Amendment # 2, effective as of April 28, 2026, to Supply Agreement, dated as of February 10, 2021, by and between Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited. |
|---|
| 2026-08-05 | 10-Q | 10.2 | Amendment # 4, effective as of April 28, 2026, to Supply Agreement, dated as of April 2, 2020, by and between Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited. |
|---|
| 2026-08-05 | 10-Q | 10.1 | Eight Amendment to Lease between CLPF-Cambridge Science Center, LLC and Akebia Therapeutics, Inc., dated April 7, 2026. |
|---|
| 2026-02-26 | 10-K | 10.98 | Amendment #1 to License Agreement by and between Cyclerion Therapeutics, Inc. and Akebia Therapeutics, Inc. dated December 13, 2024 |
|---|
| 2026-02-26 | 10-K | 10.97 | License Agreement by and between Cyclerion Therapeutics, Inc. and Akebia Therapeutics, Inc. dated June 3, 2021 |
|---|
| 2026-02-26 | 10-K | 10.96 | Asset Purchase Agreement by and between Akebia Therapeutics, Inc., Q32 Bio Inc. and Q32 Bio Operations Inc. dated November 28, 2025 |
|---|
| 2026-02-26 | 10-K | 10.91 | Amendment #1 to License Agreement, dated November 12, 2025, by and between Akebia Therapeutics, Inc. and MEDICE Arzneimittel Pütter GmbH & Co. KG |
|---|
| 2026-02-26 | 10-K | 10.45 | Form of Officer Stock Option Agreement under 2023 Stock Incentive Plan (Reflecting C-Level ESA Terms) |
|---|
| 2026-02-26 | 10-K | 10.44 | Form of Officer Restricted Stock Agreement under 2023 Stock Incentive Plan (Reflecting C-Level ESA Terms) |
|---|
| 2026-02-26 | 10-K | 10.43 | Form of Officer Stock Option Agreement under 2023 Stock Incentive Plan (Reflecting C-Level ESA Terms and Clawback Policy) |
|---|
| 2026-02-26 | 10-K | 10.42 | Form of Officer Restricted Stock Unit Agreement under 2023 Stock Incentive Plan (Reflecting C-Level ESA Terms and Clawback Policy) |
|---|
| 2026-02-26 | 10-K | 10.16 | 2026 Form of Executive Severance Agreement for Non-CEO C-Level Executives |
|---|
| 2026-02-26 | 10-K | 10.14 | Amended and Restated Executive Severance Agreement, dated January 28, 2026, between Akebia Therapeutics, Inc. and John P. Butler |
|---|
| 2026-02-26 | 10-K | 10.11 | Akebia Therapeutics, Inc. Fifth Amended and Restated Non-Employee Director Compensation Program, effective January 26, 2026 |
|---|
| 2026-02-26 | 10-K | 10.10 | 180 CityPoint Waltham, Massachusetts Lease Agreement Between BP Third Avenue LLC and Akebia Therapeutics, Inc. dated January 27, 2026 |
|---|